Study S000188

A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07255209
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 180
Start: 2025-12-29
Primary completion: 2027-10-31
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Interventions: DRUG:Placebo; DRUG:IBI362
Results posted: FALSE

Registered primary outcomes

Percent Change from Baseline in BMI [Week 32]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.